Budesonide / formoterol in treatment of exacerbations of COPD

Study identifier:SD-039-0698

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Effects of high dose inhaled budesonide+ formoterol versus placebo and oral prednisolone on biomarkers of airway inflammation in the treatment of exacerbations in non-hospitalised patients with mild to moderate COPD.

Medical condition

Chronic obstructive pulmonary disease (COPD)

Phase

Phase 2

Healthy volunteers

Study drug

budesonide/formoterol, 2x 200/6 microgram. 4 times daily, prednisolone, 30 mg once daily and placebo

Sex

All

Actual Enrollment

120

Study type

Interventional

Age

40 Years +

Date

Study Start Date: 01 Jan 2001

Primary Completion Date: -

Study Completion Date: 01 Jan 2005

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Groningen, Netherlands

Arms	Assigned Interventions

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1105&filename=CSR-SD-039-0698.pdf
Download
CSR-SD-039-0698.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Netherlands Information Center

+31 (0)79 363 22 22

Investigators

Principal Investigator

AstraZeneca Netherlands Medical Director

AstraZeneca